<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Challenges in modern medicine</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2687-0940-2020-43-2-187-195</article-id><article-id pub-id-type="publisher-id">20</article-id><article-categories><subj-group subj-group-type="heading"><subject>INTERNAL DISEASES</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;FEATURES OF CLINICAL AND ENDOSCOPIC MANIFESTATIONS OF GERD IN PATIENTS ON AMBULATORY RECEPTION&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;FEATURES OF CLINICAL AND ENDOSCOPIC MANIFESTATIONS OF GERD IN PATIENTS ON AMBULATORY RECEPTION&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Turchina</surname><given-names>Maria S.</given-names></name><name xml:lang="en"><surname>Turchina</surname><given-names>Maria S.</given-names></name></name-alternatives><email>turchina-57@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Lupanov</surname><given-names>M. I.</given-names></name><name xml:lang="en"><surname>Lupanov</surname><given-names>M. I.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Bukreeva</surname><given-names>M. V.</given-names></name><name xml:lang="en"><surname>Bukreeva</surname><given-names>M. V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Annenkova</surname><given-names>J. E.</given-names></name><name xml:lang="en"><surname>Annenkova</surname><given-names>J. E.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2020</year></pub-date><volume>43</volume><issue>2</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2020/2/187-195.pdf" /><abstract xml:lang="ru"><p>Currently, in Russia, as well as throughout the world, there is a tendency towards an increase in the incidence and prevalence of gastroesophageal reflux disease. This condition is characterized by a significant decrease in the quality of life of patients and the frequent development of relapses. At the same time, the majority of patients, due to the delay in making the correct diagnosis and low compliance with therapy, receive inadequate treatment. Often patients do not take the most effective drugs or do not adhere to the timing of treatment. The vast majority of patients with GERD are patients at clinics. Moreover, due to the lack of time on an outpatient basis, insufficient attention is paid to such patients. Based on the foregoing, it is necessary to continue research aimed at finding the most optimal ways to treat GERD and ways to increase compliance. This paper discusses the features of the clinic and diagnosis of GERD at the outpatient stage among the population of the Oryol region, analyzes the treatment results of such patients with an assessment of their quality of life.</p></abstract><trans-abstract xml:lang="en"><p>Currently, in Russia, as well as throughout the world, there is a tendency towards an increase in the incidence and prevalence of gastroesophageal reflux disease. This condition is characterized by a significant decrease in the quality of life of patients and the frequent development of relapses. At the same time, the majority of patients, due to the delay in making the correct diagnosis and low compliance with therapy, receive inadequate treatment. Often patients do not take the most effective drugs or do not adhere to the timing of treatment. The vast majority of patients with GERD are patients at clinics. Moreover, due to the lack of time on an outpatient basis, insufficient attention is paid to such patients. Based on the foregoing, it is necessary to continue research aimed at finding the most optimal ways to treat GERD and ways to increase compliance. This paper discusses the features of the clinic and diagnosis of GERD at the outpatient stage among the population of the Oryol region, analyzes the treatment results of such patients with an assessment of their quality of life.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>gastroesophageal reflux disease</kwd><kwd>prevalence</kwd><kwd>fibrogastroduodenoscopy</kwd><kwd>GERD-Q questionnaire</kwd><kwd>quality of life</kwd><kwd>outpatient care</kwd></kwd-group><kwd-group xml:lang="en"><kwd>gastroesophageal reflux disease</kwd><kwd>prevalence</kwd><kwd>fibrogastroduodenoscopy</kwd><kwd>GERD-Q questionnaire</kwd><kwd>quality of life</kwd><kwd>outpatient care</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Ivashkin V.T., Mayev I.V., A.S. Trukhmanov I., Baranskaya Y.K., Dronova O.B., Zayratyants O.V., Sayfutdinov R.G., Sheptulin A.A., Lapina T.L., Pirogov S.S., Kucheryavy Y.A., Storonova O.A., Andreyev D.N. 2017. Klinicheskie rekomendacii Rossijskoj gastroenterologicheskoj associacii po diagnostike i lecheniyu gastroezofageal&amp;#39;noj reflyuksnoj bolezni [Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological association]. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii, 27 (4): 75&amp;ndash;95.</mixed-citation></ref><ref id="B2"><mixed-citation>Lazebnik L.B., Masharova A.A., Bordin D.S., Vasil&amp;#39;ev Yu.V., Tkachenko E.I., Abdulha-kov R.A., Butov M.A., Eremina E.Yu., Zinchuk L.I., Cukanov V.V. 2009. Mnogocentrovoe issledovanie &amp;laquo;Epidemiologiya Gastroezofageal&amp;#39;noj reflyuksnoj bolezni v Rossii (MEGRE): pervye itogi&amp;raquo; [Multicenter&amp;nbsp;study &amp;laquo;Epidemiology of Gastroesophageal Reflux Disease in Russia (MEGRE): First Results&amp;raquo;]. Eksperi-mental&amp;#39;naya i klinicheskaya gastroenterologiya, 6: 4&amp;ndash;12.</mixed-citation></ref><ref id="B3"><mixed-citation>Morozov S.V., Kucheryavyj Yu.A. 2013. Lechenie bol&amp;#39;nyh neerozivnoj formoj gastroezo-fageal&amp;#39;noj reflyuksnoj bolezni [Treatment of patients with a non-erosive form of gastroesophageal reflux disease. Modern view of the problem]. Sovremennyj vzglyad na problemu. Lechashchij Vrach, 7: 32&amp;ndash;41.</mixed-citation></ref><ref id="B4"><mixed-citation>Morozov S.V., Kucheryavyj Yu.A., Kropotchev V.S. 2018. Lechenie bol&amp;#39;nyh erozivnym ezo-fagitom. Sovremennyj vzglyad na problemu [Treatment of patients with erosive esophagitis], Medicinskij sovet, 6: 66&amp;ndash;102.</mixed-citation></ref><ref id="B5"><mixed-citation>Starostin B.D. 2019. Sovremennye podhody k lecheniyu gastroezofageal&amp;#39;noj reflyuksnoj bolezni [Contemporary Approaches to the Treatment of Gastroesophageal Reflux Disease]. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii, 29 (1): 7&amp;ndash;16.</mixed-citation></ref><ref id="B6"><mixed-citation>Oskretkov V.I., Gankov V.A., Andreasyan A.R., Ovsepyan M.A. 2018. Sopostavlenie rezul&amp;#39;ta-tov anketnogo oprosa i special&amp;#39;nyh metodov issledovaniya bol&amp;#39;nyh gastroezofageal&amp;#39;noj reflyuksnoj bolezn&amp;#39;yu [Comparison of the results of a questionnaire survey and special research methods for patients with gastroesophageal reflux disease]. Endoskopicheskaya hirurgiya, 4 (6): 29&amp;ndash;32.</mixed-citation></ref><ref id="B7"><mixed-citation>Oskretkov V.I., Gankov V.A., Gur&amp;#39;yanov A.A., Klimov A.G, Andreasyan A.R., Ovsepyan M.A. 2016. Kachestvo zhizni bol&amp;#39;nyh gastroezofageal&amp;#39;noj reflyuksnoj bolezn&amp;#39;yu s aksial&amp;#39;noj gryzhej pishchevodnogo otverstiya diafragmy posle dozirovannoj ezofagofundoplikacii [Quality of life of patients with gastroesophageal reflux disease with axial hiatal hernia after dosed esophagofundoplica-tion.]. Vestnik hirurgicheskoj gastroenterologii, 4: 11&amp;ndash;15.</mixed-citation></ref><ref id="B8"><mixed-citation>Ichikawa H., Sugimoto M., Sugimoto K., Andoh A., Furuta T. 2016. Rapid metabolizer geno-type of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esopha-gitis. J. Gastroenterol. Hepatol., 31(4): 716&amp;ndash;726.</mixed-citation></ref><ref id="B9"><mixed-citation>Iwakiri K., Kinoshita Y., Habu Y., Oshima T., Manabe N., Fujiwara Y., Nagahara A., Kawamura O., Iwakiri R., Ozawa S., Ashida K., Ohara S., Kashiwagi H., Adachi K., Higuchi K., Miwa H., Fujimoto K., Kusano M., Hoshihara Y., Kawano T., Haruma K., Hongo M., Sugano K., Watanabe M., Shimosegawa T. 2016. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J. Gastroenterology, 51: 751&amp;ndash;767.</mixed-citation></ref><ref id="B10"><mixed-citation>Fujimoto K., Hongo M. 2011. Maintenance Study Group. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. Intern. Med., 50: 179&amp;ndash;188.</mixed-citation></ref><ref id="B11"><mixed-citation>Furuta K., Adachi K., Aimi M., Shimura S., Mikami H., Nishimura N., Ishimura N., Ishi-hara S., Naora K., Kinoshita Y. 2016. Effect of timing of proton pump inhibitor administration on acid suppression. Digestion., 93: 111&amp;ndash;120.</mixed-citation></ref><ref id="B12"><mixed-citation>Katz P.O., Gerson L.B., Vela M.F. 2013. Guidelines for the diagnosis and management of gas-troesophageal reflux disease. Am. J. Gastroenterol., 108 (3): 308&amp;ndash;28.</mixed-citation></ref><ref id="B13"><mixed-citation>Kinoshita Y., Kato M., Fujishiro M., Masuyama H., Nakata R., Abe H., Kumagai S., Fukushima Y., Okubo Y., Hojo S., Kusano M. 2018. Efficacy and safety of twice daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: The Japan-based EXTEND study. J. Gastroenterol., 53 (7): 834&amp;ndash;844.</mixed-citation></ref><ref id="B14"><mixed-citation>Koukias N., Woodland P., Yazaki E. 2015. Supragastric Belching: Prevalence and association with gastroesophageal reflux disease and esophageal hypomotility. J. Neurogastroenterol. Motil., 21 (3): 398&amp;ndash;403.</mixed-citation></ref><ref id="B15"><mixed-citation>Lee S.W., Lee T.Y., Lien H.C., Yeh H.Z., Chang C.S., Ko C.W. 2013. Comparison of risk fac-tors and disease severity between old and young patients with gastroesophageal reflux disease. Gastroenterol. Res., 6: 91&amp;ndash;94.</mixed-citation></ref><ref id="B16"><mixed-citation>Miner Ph., Orr W., Filippone J., Jokubaitis L., Sloan S. 2002. Rabeprazole in Nonerosive Gas-troesophageal Reflux Disease: A Randomized PlaceboControlled Trial. Am. J. Gastroenterol., 97 (6): 1332&amp;ndash;1339.</mixed-citation></ref><ref id="B17"><mixed-citation>Ndraha S. 2011. Combination of PPI with a prokinetic drug in GERD. Acta. Med. Indones-Indones. J. Intern. Med., 43 (4): 233&amp;ndash;236.</mixed-citation></ref><ref id="B18"><mixed-citation>Ness-Jensen E., Hveem K., El-Serag H. Lagergren J. 2016. Lifestyle intervention in gas-troesophageal reflux disease. Clin. Gastroenterol. Hepatol., 14 (2): 175&amp;ndash;182.</mixed-citation></ref><ref id="B19"><mixed-citation>Reimer C., L&amp;oslash;drup A.B., Smith G., Wilkinson J., Bytzer P. 2016. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment. Pharmacol. Ther., 43 (8): 899&amp;ndash;909.</mixed-citation></ref><ref id="B20"><mixed-citation>Singh S., Garg S.K., Singh P.P., Iyer P.G., El-Serag H.B. 2014. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett&amp;lsquo;s oesophagus: a systematic review and meta-analysis. Gut., 63 (8): 1229&amp;ndash;1237.</mixed-citation></ref><ref id="B21"><mixed-citation>Toghanian S., Johnson D.A., St&amp;aring;lhammar N.O., Zerbib F. 2011. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: a post hoc analysis of the 2007 national health and wellness survey. Clin. Drug. Investig., 31: 703&amp;ndash;15.</mixed-citation></ref><ref id="B22"><mixed-citation>Velanovich V. 2007. The development of the GERD-HRQL symptom severity instrument. Diseases of the Esophagus., 20: 130&amp;ndash;134.</mixed-citation></ref></ref-list></back></article>